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Objective:  To study the prevalence of platelet alloimmunisation and to characterize the 
platelet alloantibodies in hematology patients refractory to platelet transfusions in an 
Indian setting. 
 
Methodology: 80 Patients with hematological disorders, and a prior history of multiple 
transfusions (minimum of 5 cellular transfusions) were included in the study, when they 
did not achieve an adequate platelet increment within 24 hours of the present platelet 
transfusion. Patients with non immunological causes of platelet refractoriness (sepsis, 
splenomegaly, bleeding, fever and auto immune thrombocytopenia) and on drugs 
producing antiplatelet antibodies were excluded.  The test was done on 4 ml of blood 
sample in EDTA if the patient met the above inclusion criteria and was found to be 
refractory to the platelet transfusion which was assessed on the basis of the corrected 
count increment (CCI). An informed consent was taken from each patient to perform the 
test after clearly describing the purpose of the study. Plasma was separated and stored at 
–80o C and underwent batch testing in PAK– 2LE kit which is a qualitative solid phase 
enzyme linked immunosorbent assay (ELISA) designed to detect IgG antibodies to HLA 
class I antigens and to epitopes on the platelet glycoproteins IIb/IIIa, Ib/IX and Ia/IIa. The 
categorical variables were analyzed with the Chi- square test and the continuous variables 
with Kruskal-Wallis and Mann- Whitney U tests. P values ≤ 0.05 were considered to be 
significant. 
 
 
Results and Conclusion:  
The prevalence of platelet alloantibodies in our study was 60%. Of the 48 patients who 
were positive for platelet antibodies, the combination of anti-HLA and HPA antibodies 
together constituted the majority of 54.2%. Anti- HLA antibodies alone contributed to 
31.25% and antibodies to HPA alone contributed to 14.6% of the positive results. The 
distribution of HPA antibodies was as follows- majority of antibodies were positive for 
GpIIb/IIIa (47.91%) followed by GpIa/IIa (29%) and the least for GpIb/IX (23%). The 
overall prevalence of anti-HLA antibodies was 51.25% and of anti-HPA antibodies was 
41.25%. This is in contrast to all previous where the prevalence of antibodies to HPA 
antigens was generally less than 10% except for the Nigerian study on antenatal women 
which reported a similar prevalence of 41% for HPA antibodies. ABO incompatibility 
impacted significantly on platelet refractoriness in the non alloimmunized group 
(p=0.004). Against the background of HLA matched platelets, being the standard of care 
for patients with platelet refractoriness, the significant contribution of HPA antibodies in 
our study highlights the importance of screening for the same and subsequent 
incorporation of relevant measures into the management strategy of these patients.    
 
 
 
 
   
